List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5779300/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm, 2014, 11, 1304-1323.	0.7	1,077
2	Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm, 2015, 12, 1997-2007.	0.7	401
3	Selective Serotonin Reuptake Inhibitors and Myocardial Infarction. Circulation, 2001, 104, 1894-1898.	1.6	290
4	Genetic Variation in Titin in Arrhythmogenic Right Ventricular Cardiomyopathy–Overlap Syndromes. Circulation, 2011, 124, 876-885.	1.6	263
5	Reversal of Left Ventricular Dysfunction Following Ablation of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2007, 18, 9-14.	1.7	259
6	Effect of Antidepressants and Their Relative Affinity for the Serotonin Transporter on the Risk of Myocardial Infarction. Circulation, 2003, 108, 32-36.	1.6	212
7	Defibrillation threshold testing: Is it really necessary at the time of implantable cardioverter-defibrillator insertion?. Heart Rhythm, 2005, 2, 456-461.	0.7	174
8	Anatomic characterization of endocardial substrate for hemodynamically stable reentrant ventricular tachycardia: Identification of endocardial conducting channels. Heart Rhythm, 2006, 3, 503-512.	0.7	157
9	Core Isolation of Critical Arrhythmia Elements for Treatment of Multiple Scar-Based Ventricular Tachycardias. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 353-361.	4.8	157
10	Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation. Heart Rhythm, 2006, 3, 1024-1028.	0.7	155
11	Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace, 2013, 15, 347-354.	1.7	151
12	Implantable Cardioverter Defibrillator Therapy in Patients with Cardiac Sarcoidosis. Journal of Cardiovascular Electrophysiology, 2012, 23, 925-929.	1.7	135
13	Magnetic Resonance Imaging for Identifying Patients With Cardiac Sarcoidosis and Preserved or Mildly Reduced Left Ventricular Function at Risk of Ventricular Arrhythmias. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1109-1115.	4.8	117
14	Arrhythmias and COVID-19. JACC: Clinical Electrophysiology, 2020, 6, 1193-1204.	3.2	117
15	Incidence and Predictors of Very Late Recurrence of Atrial Fibrillation After Ablation. Journal of Cardiovascular Electrophysiology, 2007, 18, 69-74.	1.7	104
16	Prospective Multicenter Experience With Cooled Radiofrequency Ablation Using High Impedance Irrigant to Target Deep Myocardial Substrate Refractory to Standard Ablation. JACC: Clinical Electrophysiology, 2018, 4, 1176-1185.	3.2	95
17	Pathophysiology and clinical management of cardiac sarcoidosis. Nature Reviews Cardiology, 2015, 12, 278-288.	13.7	89
18	Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival. Heart Rhythm, 2018, 15, 48-55.	0.7	89

#	Article	IF	CITATIONS
19	Atrioventricular Nodal Reentrant Tachycardia in Patients Referred for Atrial Fibrillation Ablation. Circulation, 2006, 114, 191-195.	1.6	88
20	Radiofrequency Ablation Using an OpenÂlrrigated Electrode Cooled With Half-Normal Saline. JACC: Clinical Electrophysiology, 2017, 3, 1103-1110.	3.2	85
21	Electrocardiographic Characteristics in Patients With Pulmonary Sarcoidosis Indicating Cardiac Involvement. Journal of Cardiovascular Electrophysiology, 2011, 22, 1243-1248.	1.7	84
22	Effect of Irrigant Characteristics on Lesion Formation After Radiofrequency Energy Delivery Using Ablation Catheters with Actively Cooled Tips. Journal of Cardiovascular Electrophysiology, 2015, 26, 792-798.	1.7	84
23	Clinical and biophysical evaluation of variable bipolar configurations during radiofrequency ablation for treatment of ventricular arrhythmias. Heart Rhythm, 2016, 13, 2161-2171.	0.7	83
24	Patient and Cardiologist Perceptions on Decision Making for Implantable Cardioverterâ€Defibrillators: A Qualitative Study. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1634-1644.	1.2	76
25	Surface electrocardiogram characteristics of atrial tachycardias occurring after pulmonary vein isolation. Heart Rhythm, 2007, 4, 1136-1143.	0.7	75
26	Outcomes of Catheter Ablation of Ventricular Tachycardia Based on Etiology in Nonischemic Heart Disease. JACC: Clinical Electrophysiology, 2018, 4, 1141-1150.	3.2	75
27	Utility of Cardiac Magnetic Resonance Imaging to Differentiate Cardiac Sarcoidosis from Arrhythmogenic Right Ventricular Cardiomyopathy. American Journal of Cardiology, 2012, 110, 575-579.	1.6	73
28	Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device. Journal of Heart and Lung Transplantation, 2010, 29, 771-776.	0.6	71
29	Central Sleep-disordered Breathing Predicts Incident Atrial Fibrillation in Older Men. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 783-791.	5.6	66
30	Reentrant and nonreentrant focal left atrial tachycardias occur after pulmonary vein isolation. Heart Rhythm, 2005, 2, 1195-1202.	0.7	65
31	Predictive Score for Identifying Survival and Recurrence Risk Profiles in Patients Undergoing Ventricular Tachycardia Ablation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006730.	4.8	65
32	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace, 2020, 22, 1147-1148.	1.7	62
33	Relationship of late potentials to the ventricular tachycardia circuit defined by entrainment. Journal of Interventional Cardiac Electrophysiology, 2009, 26, 21-29.	1.3	55
34	Predictors of success after selective pulmonary vein isolation of arrhythmogenic pulmonary veins for treatment of atrial fibrillation. Heart Rhythm, 2006, 3, 165-170.	0.7	54
35	Predictors of Cardiac Sarcoidosis Using Commonly Available Cardiac Studies. American Journal of Cardiology, 2013, 112, 280-285.	1.6	53
36	Safety of Ventricular Tachycardia Ablation in Clinical Practice. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 362-370.	4.8	53

#	Article	IF	CITATIONS
37	Longer Duration Versus Increasing Power During Radiofrequency Ablation Yields Different Ablation Lesion Characteristics. JACC: Clinical Electrophysiology, 2018, 4, 902-908.	3.2	53
38	First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288. Journal of Psychopharmacology, 2017, 31, 434-441.	4.0	50
39	Incidence and predictors of mortality following ablation of ventricular tachycardia in patients with an implantable cardioverter-defibrillator. Heart Rhythm, 2010, 7, 9-14.	0.7	47
40	Effect of catheter movement and contact during application of radiofrequency energy on ablation lesion characteristics. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 123-129.	1.3	47
41	The effect of selective serotonin reâ€uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. British Journal of Clinical Pharmacology, 2011, 72, 514-517.	2.4	43
42	Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor Polymorphism. JACC: Heart Failure, 2013, 1, 338-344.	4.1	43
43	Sex and Catheter Ablation for Ventricular Tachycardia. JAMA Cardiology, 2016, 1, 938.	6.1	43
44	Identification and Characterization of Sites Where Persistent Atrial Fibrillation Is Terminated by Localized Ablation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005258.	4.8	43
45	Hemodynamic Support in VentricularÂTachycardia Ablation. JACC: Clinical Electrophysiology, 2017, 3, 1534-1543.	3.2	42
46	Titin and desmosomal genes in the natural history of arrhythmogenic right ventricular cardiomyopathy. Journal of Medical Genetics, 2014, 51, 669-676.	3.2	41
47	Diagnostic Utility of Signal-Averaged Electrocardiography for Detection of Cardiac Sarcoidosis. , 2011, 16, 70-76.		39
48	Ventricular Tachycardia Storm Successfully Treated With Immunosuppression and Catheter Ablation in a Patient With Cardiac Sarcoidosis. Journal of Cardiovascular Electrophysiology, 2010, 22, no-no.	1.7	36
49	New-onset Atrial Fibrillation Predicts Heart Failure Progression. American Journal of Medicine, 2014, 127, 963-971.	1.5	36
50	Outcomes after repeat ablation of ventricular tachycardia in structural heart disease: An analysis from the International VT Ablation Center Collaborative Group. Heart Rhythm, 2017, 14, 991-997.	0.7	36
51	Perioperative electrophysiology study in patients with tetralogy of Fallot undergoing pulmonary valve replacement will identify those at high risk of subsequent ventricular tachycardia. Heart Rhythm, 2018, 15, 679-685.	0.7	36
52	Effect of radiofrequency energy delivery in proximity to metallic medical device components. Heart Rhythm, 2015, 12, 2162-2169.	0.7	35
53	Effect of Left Ventricular Assist Device Placement on Preexisting Implantable Cardioverter-defibrillator Leads. Journal of Cardiac Failure, 2010, 16, 327-331.	1.7	34
54	Interaction of Localized Drivers and Disorganized Activation in Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005846.	4.8	33

#	Article	IF	CITATIONS
55	Safety and outcomes of catheter ablation for atrial fibrillation in adults with congenital heart disease: AÂmulticenter registry study. Heart Rhythm, 2019, 16, 846-852.	0.7	33
56	Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart, 2016, 102, 411-414.	2.9	32
57	Percutaneous transhepatic access for catheter ablation of cardiac arrhythmias. Europace, 2013, 15, 494-500.	1.7	31
58	Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias With Bucindolol in Patients With Chronic Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 137-143.	4.8	31
59	Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results) Tj ETQq1 1 0.7 Cardiology, 2003, 91, 803-806.	84314 rgl 1.6	3T /Overlock 29
60	Substrate Modification Using Stereotactic Radioablation to Treat Refractory Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy. JACC: Clinical Electrophysiology, 2022, 8, 49-58.	3.2	29
61	Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function. Journal of the American Heart Association, 2015, 4, e001566.	3.7	27
62	Relationship between coronary angioplasty laboratory volume and outcomes after hospital discharge. American Heart Journal, 2002, 143, 833-840.	2.7	26
63	Use of Tissue Electric and Ultrasound Characteristics to Predict and Prevent Steam-Generated Cavitation During High-Power Radiofrequency Ablation. JACC: Clinical Electrophysiology, 2018, 4, 491-500.	3.2	26
64	Electrophysiologic testing for diagnostic evaluation and risk stratification in patients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function. Journal of Cardiovascular Electrophysiology, 2019, 30, 1939-1948.	1.7	26
65	Insulin Sensitizing Pharmacotherapy for Prevention of Myocardial Infarction in Patients With Diabetes Mellitus. American Journal of Cardiology, 2006, 97, 651-654.	1.6	25
66	Carbon Nanotube Facilitation of Myocardial Ablation with Radiofrequency Energy. Journal of Cardiovascular Electrophysiology, 2014, 25, 1385-1390.	1.7	25
67	Enhanced Radiofrequency Ablation With Magnetically Directed Metallic Nanoparticles. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	23
68	Inappropriate Shocks due to Subcutaneous Air in a Patient With a Subcutaneous Cardiac Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 768-770.	4.8	22
69	Polysomnographic Heart Rate Variability Indices and Atrial Ectopy Associated WithÂIncident Atrial Fibrillation Risk in Older Community-Dwelling Men. JACC: Clinical Electrophysiology, 2017, 3, 451-460.	3.2	22
70	Bucindolol for the Maintenance of SinusÂRhythm in a Genotype-Defined HFÂPopulation. JACC: Heart Failure, 2019, 7, 586-598.	4.1	22
71	Bipolar radiofrequency ablation creates different lesion characteristics compared to simultaneous unipolar ablation. Journal of Cardiovascular Electrophysiology, 2019, 30, 2960-2967.	1.7	22
72	Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis. JAMA Cardiology, 2022, 7, 175.	6.1	22

#	Article	IF	CITATIONS
73	Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction. American Journal of Cardiology, 2004, 94, 1171-1173.	1.6	21
74	Absent ventricular tachycardia detection in a biventricular implantable cardioverter-defibrillator due to intradevice interaction with a rate smoothing pacing algorithm. Heart Rhythm, 2004, 1, 728-731.	0.7	20
75	Electrophysiologic manifestations of cardiac sarcoidosis. Current Opinion in Pulmonary Medicine, 2013, 19, 485-492.	2.6	20
76	Longitudinal relationships of periodic limb movements during sleep and incident atrial fibrillation. Sleep Medicine, 2016, 25, 78-86.	1.6	20
77	Impact of epicardial adipose tissue and catheter ablation strategy on biophysical parameters and ablation lesion characteristics. Journal of Cardiovascular Electrophysiology, 2020, 31, 1114-1124.	1.7	20
78	High-power bipolar ablation for incessant ventricular tachycardia utilizing a deep midmyocardial septal circuit. HeartRhythm Case Reports, 2015, 1, 397-400.	0.4	19
79	Effects of radiofrequency energy delivered through partially insulated metallic catheter tips on myocardial tissue heating and ablation lesion characteristics. Heart Rhythm, 2015, 12, 623-630.	0.7	18
80	Cardiac Sarcoidosis: When and How to Treat Inflammation. Cardiac Failure Review, 2021, 7, e17.	3.0	18
81	Increasing Left Ventricular Pacing Output Decreases Interventricular Conduction Time in Patients with Biventricular Pacing Systems. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 569-573.	1.2	17
82	Effect of Environmental Impedance Surrounding a Radiofrequency Ablation Catheter Electrode on Lesion Characteristics. Journal of Cardiovascular Electrophysiology, 2017, 28, 564-569.	1.7	16
83	Repeat ablation of refractory ventricular arrhythmias in patients with nonischemic cardiomyopathy: Impact of midmyocardial substrate and role of adjunctive ablation techniques. Journal of Cardiovascular Electrophysiology, 2018, 29, 1403-1412.	1.7	16
84	Incidence and Predictors of Late Complete Heart Block After Alcohol Septal Ablation Treatment of Hypertrophic Obstructive Cardiomyopathy. Journal of Interventional Cardiology, 2015, 28, 90-97.	1.2	15
85	Termination of persistent atrial fibrillation by ablating sites that control large atrial areas. Europace, 2020, 22, 897-905.	1.7	15
86	Covering sleeves can shield the high-voltage coils from lead chatter in an integrated bipolar ICD lead. Europace, 2007, 9, 137-142.	1.7	14
87	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009203.	4.8	14
88	Arrhythmogenic Potential of Pulmonary Venous Tissue: Triggers for Atrial Fibrillation Identified within the Remnant of a Vein. Journal of Cardiovascular Electrophysiology, 2009, 20, 441-444.	1.7	13
89	In-Hospital Complications Associated With Reoperations of Implantable Cardioverter Defibrillators. American Journal of Cardiology, 2014, 114, 419-426.	1.6	13
90	Heart Block After Discharge in Patients Undergoing TAVR With Latest-Generation Valves. Journal of the American College of Cardiology, 2018, 71, 577-578.	2.8	13

#	Article	IF	CITATIONS
91	Long term followâ€up after ventricular tachycardia ablation in patients with congenital heart disease. Journal of Cardiovascular Electrophysiology, 2019, 30, 1560-1568.	1.7	13
92	Utility of Postoperative Testing of Implantable Cardioverterâ€Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 186-192.	1.2	12
93	Use of Stored Implanted Cardiac Defibrillator Electrograms in Catheter Ablation of Ventricular Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 76-85.	1.2	12
94	Preprocedural Imaging in Patients with Transposition of the Great Arteries Facilitates Placement of Cardiac Resynchronization Therapy Leads. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 546-553.	1.2	12
95	Vectorcardiographic predictors of ventricular arrhythmia inducibility in patients with tetralogy of Fallot. Journal of Electrocardiology, 2015, 48, 141-144.	0.9	12
96	Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients. American Journal of Cardiology, 2004, 94, 479-481.	1.6	11
97	Gadolinium Augmentation of MyocardialÂTissue Heating During Radiofrequency Ablation. JACC: Clinical Electrophysiology, 2015, 1, 177-184.	3.2	11
98	Noninvasive Predictors of VentricularÂArrhythmias in Patients With Tetralogy ofÂFallot Undergoing PulmonaryÂValveÂReplacement. JACC: Clinical Electrophysiology, 2017, 3, 162-170.	3.2	11
99	Use of halfâ€normal saline irrigant with cooled radiofrequency ablation within the great cardiac vein to ablate premature ventricular contractions arising from the left ventricular summit. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 301-305.	1.2	10
100	Limitations of current risk-adjustment models in the era of coronary stenting. American Heart Journal, 2003, 145, 683-692.	2.7	9
101	Sequential dual chamber extrastimulation: A novel pacing maneuver to identify the presence of a slowly conducting concealed accessory pathway. Heart Rhythm, 2008, 5, 248-252.	0.7	9
102	Endocardial Electrogram Characteristics of Epicardial Ventricular Arrhythmias. Journal of Cardiovascular Electrophysiology, 2013, 24, 649-654.	1.7	9
103	Catheter ablation of atrial fibrillation and left atrial flutter in a patient with a left atrial appendage occlusion device. Europace, 2014, 16, 651-651.	1.7	9
104	Ventricular Tachycardia Ablation in the Elderly. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	9
105	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal, 2018, 199, 51-58.	2.7	9
106	Analysis of Outcomes in 8304 Patients Undergoing Lead Extraction for Infection. Journal of the American Heart Association, 2020, 9, e011473.	3.7	9
107	Unintentional magnet reversion of an implanted cardiac defibrillator by an electronic cigarette. HeartRhythm Case Reports, 2020, 6, 121-123.	0.4	9
108	Underestimation of Pacing Threshold as Determined by an Automatic Ventricular Threshold Testing Algorithm. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 1028-1030.	1.2	8

#	Article	IF	CITATIONS
109	Atrial Fibrillation Ablation Without Pulmonary Vein Isolation in a Patient with Fontan Palliation. Cardiac Electrophysiology Clinics, 2016, 8, 161-164.	1.7	8
110	Getting to the right left atrium: Catheter ablation of atrial fibrillation and mitral annular flutter in cor triatriatum. HeartRhythm Case Reports, 2016, 2, 502-505.	0.4	8
111	Spatial relationship of sites for atrial fibrillation drivers and atrial tachycardia in patients with both arrhythmias. International Journal of Cardiology, 2017, 248, 188-195.	1.7	8
112	Wavefront Field Mapping Reveals a Physiologic Network Between Drivers Where Ablation Terminates Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006835.	4.8	8
113	Follow-Up After CatheterÂAblation of Papillary Muscles and Valve Cusps. JACC: Clinical Electrophysiology, 2019, 5, 1185-1196.	3.2	8
114	Impact of Alcohol Consumption on Atrial Fibrillation Outcomes Following Pulmonary Vein Isolation. Journal of Atrial Fibrillation, 2016, 9, 1505.	0.5	8
115	A Dire Reaction: Rash after Amiodarone Administration. American Journal of Medicine, 2013, 126, 301-303.	1.5	7
116	Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy. Annals of Noninvasive Electrocardiology, 2016, 21, 443-449.	1.1	7
117	Noninvasive predictors of perioperative atrial arrhythmias in patients with tetralogy of Fallot undergoing pulmonary valve replacement. Clinical Cardiology, 2017, 40, 591-596.	1.8	7
118	Fasciculoventricular and atrioventricular accessory pathways in patients with Danon disease and preexcitation: A multicenter experience. Heart Rhythm, 2021, 18, 1194-1202.	0.7	7
119	Successful atrial fibrillation ablation without pulmonary vein isolation utilizing focal impulse and rotor mapping in an atriopulmonary Fontan. HeartRhythm Case Reports, 2018, 4, 241-246.	0.4	6
120	Esophageal position, measured luminal temperatures, and risk of atrioesophageal fistula with atrial fibrillation ablation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 458-463.	1.2	6
121	Open surgical ablation of ventricular tachycardia: Utility and feasibility of contemporary mapping and ablation tools. Heart Rhythm O2, 2021, 2, 271-279.	1.7	6
122	Cardiac Sarcoidosis and Consequent Arrhythmias. Cardiac Electrophysiology Clinics, 2015, 7, 235-249.	1.7	5
123	2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of) Tj ETQq1	l 0.78431 4.8	4 rgBT /Ove 5
124	Direct Thrombin Inhibitors as an Alternative to Heparin During CatheterÂAblation. JACC: Clinical Electrophysiology, 2020, 6, 484-490.	3.2	5
125	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the <i>ADRB1</i> Arg389Arg Genotype. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009591.	4.8	5
126	Perpendicular Catheter Orientation During Papillary Muscle Ablation Results in Larger, Deeper Lesions. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	5

#	Article	IF	CITATIONS
127	P-Wave Rejection in a Transplanted Heart. , 2011, 16, 308-310.		4
128	Left Ventricular Systolic Function Following Alcohol Septal Ablation for Symptomatic Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2014, 113, 1401-1404.	1.6	4
129	Antidromic Atrioventricular Reciprocating Tachycardia Using a Concealed Retrograde Conducting Left Lateral Accessory Pathway. Cardiac Electrophysiology Clinics, 2016, 8, 37-43.	1.7	4
130	Ablation of atrial arrhythmias in patients with cardiogenic shock on mechanical circulatory support. HeartRhythm Case Reports, 2019, 5, 115-119.	0.4	4
131	Continuous ablation improves lesion maturation compared with intermittent ablation strategies. Journal of Cardiovascular Electrophysiology, 2020, 31, 1687-1693.	1.7	4
132	Typical Atrial Flutter in an Atypical Patient. Congenital Heart Disease, 2011, 6, 665-667.	0.2	3
133	Ventricular Tachycardia in a Patient with Biventricular Noncompaction. Cardiac Electrophysiology Clinics, 2016, 8, 139-144.	1.7	3
134	With Great Power Comes Great Responsibility. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007456.	4.8	3
135	Complex Re-Entrant Arrhythmias Involving the His-Purkinje System. JACC: Clinical Electrophysiology, 2020, 6, 1488-1498.	3.2	3
136	Spontaneous Premature Atrial Depolarization Proving the Mechanism of a Wide Complex Tachycardia. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1625-1627.	1.2	2
137	A Potential Paraâ€Hisian Pacing Pitfall. Journal of Cardiovascular Electrophysiology, 2009, 20, 448-448.	1.7	2
138	Unusual Fibrillation in the Emergency Department After Fall. Circulation, 2011, 123, e641-2.	1.6	2
139	The Tribulations of Atrial Fibrillation Ablation Trialists. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003738.	4.8	2
140	Non-invasive Thoracic Impedance Changes in COVID-19 Pulmonary Infection. Journal of Cardiovascular Translational Research, 2021, 14, 387-389.	2.4	2
141	Uncovering a unique path: Antidromic AVRT utilizing a left anteroseptal Mahaimâ€like accessory pathway. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 185-188.	1.2	2
142	Site specific indices of epicardial ventricular tachycardia site of origin. Heart Rhythm, 2005, 2, S158-S159.	0.7	1
143	P2-25. Heart Rhythm, 2006, 3, S146.	0.7	1
144	P5-63. Heart Rhythm, 2006, 3, S281.	0.7	1

#	Article	IF	CITATIONS
145	P4-38. Heart Rhythm, 2006, 3, S230-S231.	0.7	1
146	Phase 4 conduction block of a right midseptal accessory pathway. Heart Rhythm, 2007, 4, 686-687.	0.7	1
147	Unusual Pacing Observed in a Biventricular Pacemaker with Epicardial Pacing Leads. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 130-4.	1.2	1
148	Paradoxical Slowing of Orthodromic Reciprocating Tachycardia with Loss of Bundle Branch Block Ipsilateral to the Accessory Pathway. Journal of Cardiovascular Electrophysiology, 2009, 20, 347-348.	1.7	1
149	A Mobile Tubular Mass Visualized by Transesophageal Echocardiography After Successful Lead Extraction. Circulation, 2011, 123, e590-1.	1.6	1
150	Incessant Supraventricular Tachycardia in a Patient with Cardiomyopathy. Cardiac Electrophysiology Clinics, 2012, 4, 517-520.	1.7	1
151	Protection of Critical Structures During Radiofrequency Ablation of Adjacent Myocardial Tissue Using Catheter Tips Partially Insulated With Thermally Conductive Material. JACC: Clinical Electrophysiology, 2016, 2, 838-846.	3.2	1
152	VT arising from subâ€aortic muscular outflow tract structures: In two patients with ventricular septal defects. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1155-1157.	1.2	1
153	Patients with bicuspid aortic valves may be associated with infra-hisian conduction disease requiring pacemakers. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 29-35.	1.3	1
154	B-AB05-03 A SAME DAY DISCHARGE STRATEGY AFTER ATRIAL FIBRILLATION ABLATION THAT IS OVERSEEN BY ALLIED HEALTH PROFESSIONALS CAN BE INITIATED SAFELY AND EFFECTIVELY. Heart Rhythm, 2021, 18, S8.	0.7	1
155	Cardiac stereotactic radiation therapy: Charting a course through unchartered waters. Heart Rhythm, 2021, 18, 2146-2147.	0.7	1
156	Catheter ablation of ventricular tachycardia in patients with prior cardiac surgery: An analysis from the International VT Ablation Center Collaborative Group. Journal of Cardiovascular Electrophysiology, 2021, 32, 409-416.	1.7	1
157	Percutaneous right ventricular assist device–supported ventricular tachycardia ablation in a patient with severe right ventricular dysfunction. HeartRhythm Case Reports, 2020, 6, 72-76.	0.4	1
158	Electrophysiologic study: its predictive value for ventricular arrhythmias. Texas Heart Institute Journal, 2010, 37, 291-6.	0.3	1
159	Impact of Variableorientation and Flow Rates on Radio Frequency Ablation Lesions Created by Externally Irrigated Catheters: An Ex-Vivo Study. Journal of Atrial Fibrillation, 2020, 13, 2353.	0.5	1
160	Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center. Rheumatology International, 2022, , 1.	3.0	1
161	CE-522-04 MORTALITY AND MORBIDITY OF CARDIAC SARCOIDOSIS: AN INTERNATIONAL REGISTRY. Heart Rhythm, 2022, 19, S28-S29.	0.7	1
162	PO-672-03 TWO FOR THE PRICE OF ONE: BIDIRECTIONAL VENTRICULAR TACHYCARDIA FROM THE ANTEROLATERAL PAPILLARY MUSCLE. Heart Rhythm, 2022, 19, S328.	0.7	1

#	Article	IF	CITATIONS
163	PO-638-02 INFLAMMATION BY FDG PET IS DISCORDANT WITH SITES OF FOCAL VENTRICULAR TACHYCARDIA IN PATIENTS WITH SUSPECTED CARDIAC SARCOIDOSIS. Heart Rhythm, 2022, 19, S196.	0.7	1
164	Increasing left ventricular pacing output decreases interventricular conduction time in patients with biventricular pacing systems. Heart Rhythm, 2005, 2, S83-S84.	0.7	0
165	Utility of late potentials for characterization of reentrant circuits in patients with uniform ventricular tachycardia. Heart Rhythm, 2005, 2, S159-S160.	0.7	0
166	P6-73. Heart Rhythm, 2006, 3, S325-S326.	0.7	0
167	Successful Treatment of Sarcoid Related Ventricular Tachycardia Storm with Immunosuppression and Catheter Ablation. Journal of Cardiac Failure, 2009, 15, S58-S59.	1.7	0
168	Implantable Cardioverter-Defibrillator Events in Patients with Left Ventricular Assist Devices. Journal of Cardiac Failure, 2009, 15, S47-S48.	1.7	0
169	Clinical Subtype of Atrial Fibrillation at the Time of Implantation and Subsequent Mortality among Veterans With Implantable Defibrillators. Journal of Cardiac Failure, 2010, 16, S58.	1.7	0
170	Supraventricular tachycardia with atrioventricular block: What is the mechanism?. Heart Rhythm, 2010, 7, 1704-1705.	0.7	0
171	Characteristics of Implantable Cardioverter-defibrillator Recipients for the Primary and Secondary Prevention of Sudden Cardiac Death in the Outcomes Among Veterans With Implantable Defibrillators (OVID) Registry. Journal of Cardiac Failure, 2011, 17, S52-S53.	1.7	0
172	Bicuspid Ventricular Tachycardia in a Patient with Syncope and a Structurally Normal Heart. Cardiac Electrophysiology Clinics, 2012, 4, 605-610.	1.7	0
173	Atrial Oversensing and Mode Switching Caused by Lead Polarization Artifact During an Automatic Ventricular Capture Threshold Test. Cardiac Electrophysiology Clinics, 2012, 4, 633-636.	1.7	0
174	Atrial Refractory Stimulation to Identify the Optimal Slow-Pathway Ablation Site for Treatment of Atypical Atrioventricular Nodal Reentrant Tachycardia. Cardiac Electrophysiology Clinics, 2012, 4, 509-512.	1.7	0
175	Effect of Bucindolol on Heart Failure Outcomes in HFREF Patients With Permanent Atrial Fibrillation. Journal of Cardiac Failure, 2012, 18, S50-S51.	1.7	0
176	Tachycardia-Induced Tachycardia. Journal of Cardiovascular Electrophysiology, 2012, 23, 1390-1392.	1.7	0
177	New Onset Atrial Fibrillation Is a Risk Factor for Ventricular Arrhythmias in Heart Failure. Journal of Cardiac Failure, 2013, 19, S24.	1.7	0
178	Emergent Catheter Ablation of VT/VF Storm Can Be Safely Performed in Patients with Severe Heart Failure. Journal of Cardiac Failure, 2013, 19, S23.	1.7	0
179	Change in QRS Duration Over Time Predicts Ventricular Tachycardia after Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2014, 20, S36.	1.7	0
180	Measured Lead Parameters and Electrogram Sensing Over Time in PatientsÂWith Cardiac Sarcoidosis andÂanÂImplanted Cardiac-Defibrillator. JACC: Clinical Electrophysiology, 2015, 1, 94-102.	3.2	0

#	Article	IF	CITATIONS
181	Generator Exchange in a Primary Prevention Cardiac Resynchronziation Responder. Cardiac Electrophysiology Clinics, 2015, 7, 487-496.	1.7	0
182	EARLY RECURRENCE OF VENTRICULAR TACHYCARDIA PREDICTS INCREASED MORTALITY AMONG PATIENTS WITH SEVERE HEART FAILURE. Journal of the American College of Cardiology, 2017, 69, 503.	2.8	0
183	Mapping repetitive activation in atrial fibrillation: Active drivers or passengers along for the ride?. Journal of Cardiovascular Electrophysiology, 2018, 29, 696-698.	1.7	Ο
184	Mapping Atrial Fibrillation and FindingÂaÂMethod to the Madness. JACC: Clinical Electrophysiology, 2019, 5, 830-832.	3.2	0
185	A Maze-ing crisscross interval plot: what is the diagnosis?. Europace, 2020, 22, 1233-1233.	1.7	Ο
186	Radiofrequency Catheter Ablation ofÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2020, 6, 153-156.	3.2	0
187	Letter from the Program Directors. Journal of Innovations in Cardiac Rhythm Management, 2021, 12, 4457-4458.	0.5	0
188	B-PO03-181 LVOT DILATATION IS ASSOCIATED WITH REDUCED PERI-AORTIC BIPOLAR VOLTAGE IN PATIENTS UNDERGOING VT ABLATION. Heart Rhythm, 2021, 18, S263.	0.7	0
189	B-AB12-01 THE PRESENCE OF UNINSULATED METALLIC ELECTRODES ON AN ESOPHAGEAL TEMPERATURE PROBE IS ASSOCIATED WITH INCREASED TEMPERATURES WHEN EXPOSED TO NEARBY RADIOFREQUENCY ELECTRICAL CURRENT. Heart Rhythm, 2021, 18, S23.	0.7	0
190	B-PO01-060 THE DELIVERY PATTERN OF RADIOFREQUENCY APPLICATIONS IN A LEFT ATRIAL-ESOPHAGEAL ABLATION MODEL DEMONSTRATES A HEAT STACK EFFECT: IMPLICATIONS FOR LEFT ATRIAL POSTERIOR WALL ABLATION. Heart Rhythm, 2021, 18, S75.	0.7	0
191	B-PO03-101 ABLATION DELIVERY PARAMETERS PREDICT IMPEDANCE DECREASE DURING ATRIAL FIBRILLATION ABLATION VIA A CLOUD ARTIFICIAL INTELLIGENCE SYSTEM ANALYSIS. Heart Rhythm, 2021, 18, S229-S230.	0.7	Ο
192	B-PO03-110 ANATOMIC LESION LOCATION DURING PULMONARY VEIN ISOLATION IMPACTS ABLATION PARAMETERS AND INDEPENDENTLY PREDICTS IMPEDANCE CHANGE AND REGIONAL FIRST PASS ISOLATION: AN ANALYSIS OF 8395 LESIONS. Heart Rhythm, 2021, 18, S233.	0.7	0
193	B-PO02-085 OBESITY IS ASSOCIATED WITH INCREASED COMORBIDITIES, BUT NOT ADVERSE OUTCOMES IN PATIENTS UNDERGOING ABLATION FOR PERSISTENT AF. Heart Rhythm, 2021, 18, S130-S131.	0.7	0
194	B-PO02-210 INFERRED INTRAMURAL ACTIVATION FACILITATED BY EPICARDIAL AND ENDOCARDIAL ACTIVATION MAPPING DURING VENTRICULAR TACHYCARDIA IN LAMIN CARDIOMYOPATHY. Heart Rhythm, 2021, 18, S184.	0.7	0
195	Increased incidence of cavotricuspid isthmus atrial flutter following slow pathway ablation. Journal of Interventional Cardiac Electrophysiology, 2021, , 1.	1.3	Ο
196	Turn It Up to Eleven. JACC: Clinical Electrophysiology, 2021, 7, 1240-1242.	3.2	0
197	HP-573-01 LESION QUALITY AND SAFETY MAINTAINED AS TRAINEES DEVELOP CATHETER HANDLING SKILLS AND PROGRESS TO INDEPENDENCE: CLOUD-BASED ANALYSIS. Heart Rhythm, 2022, 19, S42-S43.	0.7	0
198	PO-632-06 REAL-TIME EX-VIVO RADIOTHERAPY IMPACTS ON PACEMAKER FUNCTION ARE MINIMAL. Heart Rhythm, 2022, 19, S174.	0.7	0

#	Article	IF	CITATIONS
199	PO-715-02 POST ABLATION QT INTERVAL AND HEART RATE INCREASES ARE ASSOCIATED WITH IMPROVED OUTCOMES AFTER PULMONARY VEIN ISOLATION. Heart Rhythm, 2022, 19, S492.	0.7	0
200	CA-530-01 USE THE FORCE: ADEQUATE CATHETER CONTACT FORCE IS CRITICAL FOR HIGH QUALITY LESIONS GUIDED BY ABLATION INDEX. Heart Rhythm, 2022, 19, S24-S25.	0.7	0
201	CA-533-01 MULTIMODALITY PLANNING OF STEREOTACTIC RADIO-ABLATION FOR VENTRICULAR TACHYCARDIA: RESULTS FROM THE INTERNATIONAL MUSIC CONSORTIUM. Heart Rhythm, 2022, 19, S57-S58.	0.7	0
202	PO-661-08 VIRTUAL CARE IN CARDIAC ELECTROPHYSIOLOGY HAS LASTING IMPACT AND IS USED MORE OFTEN COMPARED TO OTHER CARDIOVASCULAR SUBSPECIALTIES. Heart Rhythm, 2022, 19, S288.	0.7	0
203	PO-634-04 FLUOROLESS CRYOBALLOON ABLATION FOR PULMONARY VEIN AND LEFT ATRIAL POSTERIOR WALL ISOLATION IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION: A SINGLE CENTER EXPERIENCE. Heart Rhythm, 2022, 19, S180-S181.	0.7	0